HOME >> MEDICINE >> NEWS
New rheumatoid arthritis drug developed at UCSD promises improved treatment options

Researchers at the University of California, San Diego (UCSD) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis (RA), one that works without suppressing the patient's immune system.

Salvatore Albani, M.D., Ph.D, professor of medicine and pediatrics and Director of the Translational Research Unit of the Clinical Investigation Institute (CII) at the UCSD School of Medicine, recently presented a summary of the findings at the "Frontiers of Clinical Investigation Symposium." The symposium, sponsored by the CII and Nature Medicine, was held in La Jolla, California in September.

The new drug, dnaJP1, is a peptide derived from a naturally occurring protein, dnaJ, which generates inflammation in RA patients, whose inflammatory-control mechanisms are impaired. The impairment causes the body's T cells which trigger inflammation to kill and clear foreign pathogens in the body to attack the body's own tissues.

"In essence, we re-educated the immune system T cells to be tolerant of the dnaJP1 amino acid sequence, which would usually contribute to inflammation in rheumatoid arthritis patients," Albani said.

DnaJP1 works by resetting the ability of the patient's immune system to tolerate dnaJ, thus transforming a potentially damaging trigger into a tool for controlling the disease. Oral ingestion of dnaJP1 is key, because the mucosal immune system found in the gut has the ability to "teach" the body to view a protein as one that isn't dangerous or foreign. Much as food is ingested into the body and not rejected, the body tolerates dnaJP1.

Current medications for treating RA range from anti-inflammatory drugs, such as aspirin, to corticosteroids and medicines that alleviate symptoms by suppressing or killing the body's immune response, basically crippling the body's ability to defend itself against other infectious diseases or cancer.


'"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2005


Page: 1 2 3

Related medicine news :

1. Green tea compound may be a therapy for people with rheumatoid arthritis
2. The link between rheumatoid arthritis and cancer
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Women with rheumatoid arthritis have significantly less chance of remission than men
5. New study reveals postcode lottery for rheumatoid arthritis treatment
6. Cancer drug may be remedy for rheumatoid arthritis, Stanford study finds
7. A new approach to rheumatoid arthritis
8. Increased odds of rheumatoid arthritis in women smokers without genetic risk factor
9. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
10. New evidence shows MabThera inhibits joint damage in patients with rheumatoid arthritis
11. PTPN22 gene associated with both susceptibility and disease progression in rheumatoid arthritis

Post Your Comments:
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... for concerns about hair loss. Although it is unclear ... that there are environmental factors such as metabolism, nutritional ... contribute. Since they offer a comprehensive approach to evaluating ... and post-menopausal woman, they can help patients find a ...
(Date:5/24/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... tests, which will allow them to take pressure measurements ... about bladder function. The doctor usually orders it if ... or overactive bladder (OAB). , Women’s Excellence ... that have problems with unwanted urinary leakage or problems ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 EnviroLeather™ ... launches “InkGard™ Plus” – a classic, rugged leather ... polymer allowing difficult stains, including ink, to be ... different colors suitable for corporate, healthcare, hospitality and ... line with EnviroLeather’s goal of developing products that ...
(Date:5/24/2015)... Viejo, CA (PRWEB) May 24, 2015 ProPin ... use in Final Cut Pro X. Utilize ProPin to pin ... in a given scene. , ProPin allows users to ... completely customizable in FCPX. With on-screen controls, video editors can ... allows users to pin and mark with absolute ease. , Using ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Medicx Media Solutions Expands Executive Team 2
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
Cached News: